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ABSTRACT
Background: We investigated and compared the initial clinical features at diagnosis and the 
poor outcomes during follow-up in Korean patients with antineutrophil cytoplasmic antibody 
(ANCA)-associated vasculitis (AAV) based on sex.
Methods: The medical records of 223 immunosuppressive drug-naïve patients with AAV were 
reviewed. Age, body mass index (BMI), smoking history, AAV subtypes, ANCA positivity, 
clinical manifestations, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) at diagnosis were collected. 
All-cause mortality, end-stage renal disease (ESRD), cerebrovascular accident (CVA) and 
cardiovascular disease (CVD) were assessed as the poor outcomes of AAV during follow-up.
Results: The median age was 59.0 years and 74 of 223 AAV patients (33.2%) were men. 
Among variables at diagnosis, male patients exhibited higher BMI than female. However, 
there were no differences in other demographic data, AAV subtypes, ANCA positivity, BVAS, 
FFS, ESR and CRP between the two groups. Male patients received cyclophosphamide more 
frequently, but there were no significant differences in the frequencies of the poor outcomes 
of AAV between the two groups. Male patients exhibited a significantly lower cumulative 
patients' survival rate than female patients during the follow-up period based on all-cause 
mortality (P = 0.037). In the multivariable analysis, both male sex (hazard ratio [HR], 2.378) 
and FFS (HR, 1.693) at diagnosis were significantly and independently associated with all-
cause mortality during follow-up.
Conclusion: Male sex is a significant and independent predictor of all-cause mortality in AAV 
patients.
Keywords: Sex; Difference; Antineutrophil Cytoplasmic Antibody Vasculitis; Clinical Features; 
Prognosis
INTRODUCTION
Based on the 2012 revised international Chapel Hill Consensus Conference nomenclature 
of vasculitides, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) 
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has currently been defined as the necrotising vasculitis without definite immune-complex 
deposition. AAV primarily affects small vessels, including small intraparenchymal arteries, 
arterioles, capillaries and venules and occasionally medium-sized arteries and veins.1 In 
addition, AAV can be further classified three subtypes based on pathogenesis, histological 
findings, clinical symptoms and signs and laboratory results such as microscopic polyangiitis 
(MPA), granulomatosis with polyangiitis (GPA) and eosinophilic GPA (EGPA).1,2
Each systemic vasculitis has its own typical sex difference in the incidence: for instance, 
among large vessel vasculitis, giant cell arteritis has the male to female ratio of 1:3, whereas 
Takayasu arteritis has the male to female ratio of 1:9.3 Moreover, each systemic vasculitis 
has a sex differences in the clinical features: for instance, with regard to Korean patients 
with Behcet's disease, female patients exhibited more frequently genital ulcers, peripheral 
arthritis, and inflammatory low back pain, whereas male patients showed a higher 
frequency of skin lesions.4 There was a previous study pertaining to the sex difference in 
AAV patients, which reported that male patients were vulnerable to the progression to 
end-stage renal disease (ESRD) compared to female patients. However, this study included 
only ANCA-positive AAV patients with histologically proven pauci-immune necrotising 
glomerulonephritis. For this reason, the results could not be generalised to all AAV patients.5 
Also, given the ethnic and geographical differences affecting both the clinical manifestation 
and the poor outcomes of AAV, a need for a study investigating the sex difference in Korean 
patients with AAV is still raised but there has been no study on it to date. Hence, in this study, 
we investigated and compared the initial clinical features at diagnosis and the poor outcomes 
during follow-up in Korean patients with AAV based on sex.
METHODS
Patients
The medical records of 223 immunosuppressive drug-naïve patients with AAV were reviewed. 
They had been initially diagnosed or reclassified as AAV at the Division of Rheumatology, 
the Department of Internal Medicine, Yonsei University College of Medicine, Severance 
Hospital, from October 2000 to March 2020. All patients met the 2007 European medicines 
Agency algorithm for polyarteritis nodosa and AAV as well as the 2012 revised International 
Chapel Hill Consensus Conference Nomenclature of Vasculitides.1,2 All patients had the 
medical records well-documented enough to either collect or assess AAV-specific indices 
including Birmingham vasculitis activity score (BVAS) version 3 and five-factor score (FFS).6,7 
They had the initial results of ANCA by both an indirect immunofluorescence assay (IFA) 
for perinuclear (P)-ANCA and cytoplasmic (C)-ANCA and an antigen-specific assay for 
myeloperoxidase (MPO)-ANCA and proteinase 3 (PR3)-ANCA. Patients negative by antigen-
specific assay but positive for ANCA by IFA were considered to have MPO-ANCA or PR3-
ANCA when AAV was strongly suspected by the clinical and laboratory features.8 Patients, 
who had serious medical conditions mimicking the clinical features of AAV at diagnosis 
such as malignancies, infectious diseases and autoimmune diseases other than AAV, were 
excluded from this study. In addition, patients, who had been received immunosuppressive 
drugs prior to diagnosis, were also excluded. All patients had been followed up for at least 
more than 3 months from the time of diagnosis.
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Clinical and laboratory data at diagnosis and during follow-up
In terms of variables at diagnosis, sex, age, body mass index (BMI) and smoking history were 
collected as demographic data. AAV subtypes, ANCA positivity, clinical features based on 
BVAS items,6 and AAV-specific indices were obtained. As acute-phase reactants, erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) were also obtained. In terms of 
variables during follow-up, all-cause mortality, ESRD, cerebrovascular accident (CVA) 
and cardiovascular disease (CVD) were assessed as the poor outcomes of AAV. ESRD was 
defined as the status requiring for renal replacement therapy due to estimated glomerular 
filtration rate of less than 15 mL/min/1.73m2.5 On the basis of sub-items of cardiovascular 
and nervous systemic items of BVAS,6 CVA was defined as both ischaemic and haemorrhagic 
strokes, whereas CVD was defined as loss of pulses, vascular heart disease, pericarditis, 
ischaemic cardiac pain, cardiomyopathy and congestive cardiac failure. Since all patients 
were classified as AAV in our institute and most of them have been followed up, we could 
easily access the medical record in our institute to obtain data on the date of death and the 
first date of diagnosis of ESRD, CVA and CVD. In addition, information regarding all-cause 
mortality, ESRD, CVA and CVD in patients, who were not followed up in our institute, could 
be obtained by the Korean National Health Insurance Service system. The follow-up period 
based on all-cause mortality was defined as the periods from the time of diagnosis of AAV 
to the death for deceased patients, and those to the last visit for survived patients. On the 
other hand, the follow-up periods based on ESRD, CVA and CVD were also defined as the 
periods from diagnosis to either the first renal-replacement, the first diagnoses of CVA or 
that of CVD, respectively. We counted the number of patients who received each drug among 
glucocorticoid and immunosuppressive drugs.
Statistical analyses
All statistical analyses were conducted using SPSS software (version 23 for Windows; IBM 
Corp., Armonk, NY, USA). Continuous variables were expressed as a mean ± standard 
deviation, and categorical variables were expressed as number and the percentage. 
Significant differences in categorical variables between the two groups were analysed using 
the χ2 and Fisher's exact tests. Significant differences in continuous variables between the 
two groups were compared using the Mann-Whitney test. Comparison of the cumulative 
survivals rates between the two groups was analysed by the Kaplan-Meier survival analysis 
with the log-rank test. The multivariable Cox hazard model using variables with statistical 
significance in the univariable Cox hazard model was conducted to appropriately obtain the 
hazard ratios (HRs) during the considerable follow-up period. P values less than 0.05 were 
considered statistically significant.
Ethics statement
This study was approved by the Institutional Review Board (IRB) of Severance Hospital (4-
2017-0673), and the patient's written informed consent was waived by the approving IRB, as 
this was a retrospective study.
RESULTS
Comparison of variables at diagnosis
The median age was 59.0 years and 74 of 223 AAV patients (64.8%) were men. AAV patients 
were divided into two groups based on sex and variables at diagnosis were compared between 
the two groups. Male patients exhibited a higher median BMI than female patients (23.2 vs. 
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22.0 kg/m2, P = 0.004). Age, smoking history, AAV subtypes, ANCA positivity and the clinical 
features based on BVAS items did not significantly differ between male and female patients. 
Also, there were no significant differences in AAV-specific indices and acute-phase reactants 
between the two groups (Table 1).
Comparison of variables during follow-up
With regard to the poor outcomes of AAV, there were no significant differences in the 
frequencies of the poor outcomes of AAV between the two groups. Among glucocorticoid 
and immunosuppressive drugs administered during follow-up, male patients received 
cyclophosphamide more frequently compared to female patients (62.2% vs. 44.3%, P = 
0.012) (Table 2).
Comparison of cumulative survival rates
Among the four poor outcomes of AAV, male patients exhibited a significantly lower 
cumulative patients' survival rate than female patients during the follow-up period based on 
all-cause mortality (P = 0.037). Meanwhile, male patients tended to have a lower CVD-free 
survival rate compared to female patients but it did not reach statistical significance (P = 
0.057) (Fig. 1).
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Table 1. Comparison of variables at diagnosis in 223 patients with AAV
Variables Male patients (n = 74) Female patients (n = 149) P value
Demographic data
Age, yr 57.0 (19.5) 59.0 (20.0) 0.892
BMI, kg/m2 23.2 (4.2) 22.0 (4.3) 0.004
Smoking history 4 (5.4) 2 (1.3) 0.077
AAV subtypes 0.405
MPA 37 (50.0) 85 (57.1)
GPA 23 (31.1) 34 (22.8)
EGPA 14 (18.9) 30 (20.1)
ANCA positivity
MPO-ANCA (or P-ANCA) positivity 48 (64.9) 100 (67.1) 0.738
PR3-ANCA (or C-ANCA) positivity 15 (20.3) 23 (15.4) 0.366
ANCA negativity 12 (16.2) 34 (22.8) 0.251
Clinical features based on BVAS items
General manifestations 28 (37.8) 68 (45.6) 0.268
Cutaneous manifestations 13 (17.6) 35 (23.5) 0.311
Mucous and ocular manifestations 3 (4.1) 10 (6.7) 0.552
Otorhinolaryngologic manifestations 35 (47.3) 67 (45.0) 0.742
Pulmonary manifestations 48 (64.9) 84 (56.4) 0.225
Cardiovascular manifestations 18 (24.3) 30 (20.1) 0.473
Gastrointestinal manifestations 5 (6.8) 7 (4.7) 0.539
Renal manifestations 50 (67.6) 86 (57.7) 0.156
Nervous systemic manifestations 27 (36.5) 41 (27.5) 0.171
AAV-specific indices
BVAS 12.0 (7.5) 12.0 (12.0) 0.383
FFS 1.0 (1.0) 1.0 (2.0) 0.071
Acute phase reactants
ESR, mm/hr 53.0 (64.5) 59.0 (74.0) 0.754
CRP, mg/L 12.8 (74.6) 11.7 (59.5) 0.328
Values are expressed as a median (interquartile range) or number (%).
ANCA = antineutrophil cytoplasmic antibody, AAV = ANCA-associated vasculitis, BMI = body mass index, MPA 
= microscopic polyangiitis, GPA = granulomatosis with polyangiitis, EGPA = eosinophilic granulomatosis with 
polyangiitis, MPO = myeloperoxidase, P = perinuclear, PR3 = proteinase 3, C = cytoplasmic, BVAS = Birmingham 
vasculitis activity score, FFS = five-factor score, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein.
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Table 2. Comparison of variables during follow-up in 223 patients with AAV
Variables Male patients (n = 74) Female patients (n = 149) P value
Poor outcomes
All-cause mortality 12 (16.2) 13 (8.7) 0.095
Follow-up period based on all-cause mortality, 
mon
22.5 (51.5) 42.1 (67.6) 0.007
ESRD 12 (16.2) 26 (17.4) 0.818
Follow-up period based on ESRD, mon 15.8 (47.0) 32.4 (71.3) 0.015
CVA 6 (8.1) 13 (8.7) 0.877
Follow-up period based on CVA, mon 21.3 (47.0) 38.6 (62.8) 0.016
CVD 7 (9.5) 5 (3.4) 0.110
Follow-up period based on CVD, mon 21.8 (46.9) 39.6 (59.8) 0.003
Medications
Glucocorticoid 69 (93.2) 138 (92.6) 0.865
Cyclophosphamide 46 (62.2) 66 (44.3) 0.012
Rituximab 7 (9.5) 21 (14.1) 0.325
Azathioprine 41 (55.4) 79 (53.0) 0.737
Mycophenolate mofetil 5 (6.8) 7 (4.7) 0.539
Tacrolimus 11 (14.9) 24 (16.1) 0.810
Methotrexate 5 (6.8) 17 (11.4) 0.344
Values are expressed as amedian (interquartile range) or number (%).
ANCA = antineutrophil cytoplasmic antibody, AAV = ANCA-associated vasculitis, ESRD = end-stage renal disease, 
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Fig. 1. Comparison of the cumulative survival rates between male and female patients with AAV. 
Among all-cause mortality, ESRD, CVA and CVD, only a cumulative patients' survival rate diffed between male and female AAV patients. Male patients exhibited a 
significantly lower cumulative patients' survival rate than female patients. 
ANCA = antineutrophil cytoplasmic antibody, AAV = ANCA-associated vasculitis, ESRD = end-stage renal disease, CVA = cerebrovascular accident, CVD = 
cardiovascular disease.
Cox hazard model analyses
In the univariable analysis, age (HR, 1.055), male sex (HR, 2.264), smoking history (HR, 
6.052), BVAS (HR, 1.096) and FFS (HR, 2.142) at diagnosis were significantly associated 
with all-cause mortality during follow-up. In the multivariable analysis, both male sex (HR, 
2.378; 95% confidence interval [CI], 1.050–5.384) and FFS (HR, 1.693; 95% CI, 1.071–2.676) 
at diagnosis were significantly and independently associated with all-cause mortality during 
follow-up (Table 3).
DISCUSSION
In this study comparing the clinical features based on the sex difference in AAV patients, 
we discovered the following three new findings. First, at the time of diagnosis, the clinical 
features and laboratory related to AAV, such as AAV subtypes, ANCA positivity, clinical 
manifestations and AAV-specific indices, did not significantly differ between male and female 
patients. Second, during the follow-up period, male patients exhibited a significantly lower 
cumulative patients' survival rate compared to female patients. Third, male sex together with 
FFS was proved to be an independent predictor of all-cause mortality during the follow-up 
period in AAV patients.
Only male sex itself does not seem to simply increase the rate of all-cause mortality in this 
study. A previous study reported introduced dietary risks, tobacco smoking, high BMI, high 
blood pressure and high fasting plasma glucose as the most common risk factors for mortality. 
However, male sex itself was not clearly defined as a primary risk factor for mortality.9 Another 
previous study denied the fact that the life expectancy of men was meaningfully lower than that 
of women. Instead, it suggested the different clinical features based on the sex difference.10 
Meanwhile, although there were no differences in clinical manifestations at diagnosis between 
male and female AAV patients, in the multivariable Cox analysis, male sex was an independent 
predictor of all-cause mortality during follow-up. It is difficult to suggest the exact mechanism, 
but it can be assumed that in a condition with persistent AAV, male patients are more frequently 
exposed to situations that may increase the rate of all-cause mortality compared to female 
patients. The result that cyclophosphamide had been administered to male patients more 
frequently than female patients during the follow-up period may support our assumption.
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Table 3. Cox hazards model analysis of variables at diagnosis for all-cause mortality during follow-up in 223 patients with AAV
Variables at diagnosis Univariable Multivariable
HR 95% CI P value HR 95% CI P value
Age 1.055 1.018–1.093 0.003 1.031 0.995–1.068 0.092
Male sex 2.264 1.029–4.978 0.042 2.378 1.050–5.384 0.038
BMI 1.094 0.955–1.252 0.195
Smoking history 6.052 1.787–20.498 0.004 2.669 0.703–10.124 0.149
MPA vs. GPA or EGPA 2.008 0.864–4.665 0.105
GPA vs. MPA or EGPA 1.431 0.616–3.324 0.405
MPO-ANCA (or P-ANCA) positivity 1.450 0.617–3.409 0.394
PR3-ANCA (or C-ANCA) positivity 0.963 0.358–2.588 0.940
BVAS 1.096 1.040–1.155 0.001 1.053 0.993–1.116 0.082
FFS 2.142 1.468–3.126 < 0.001 1.693 1.071–2.676 0.024
ESR 1.003 0.993–1.013 0.539
CRP 1.005 0.999–1.011 0.073
ANCA = antineutrophil cytoplasmic antibody, AAV = ANCA-associated vasculitis, HR = hazard ratio, CI = confidence interval, BMI = body mass index, MPA = 
microscopic polyangiitis, GPA = granulomatosis with polyangiitis, EGPA = eosinophilic GPA, MPO = myeloperoxidase, P = perinuclear, PR3 = proteinase 3, C = 
cytoplasmic, BVAS = Birmingham vasculitis activity score, FFS = five-factor score, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein.
At diagnosis, male patients showed a higher mean BMI than female patients.
We wondered whether a high BMI in male patients has influenced an increase in all-cause 
mortality compared to female patients. To get the clue to prove this, we compared BMI between 
survived and dead patients with AAV and found that there was no significant difference between 
the two groups (22.1 vs. 23.0 kg/m2, P = 0.292). In addition, in the multivariable Cox analysis, 
BMI was not significantly associated with all-cause mortality (Table 3). Why did not the high 
calculated BMI in male patients contribute to an increased all-cause mortality rate in male 
patients? According to the previous studies, the rate of all-cause mortality showed a U-shape 
with BMI between 22.5 and 25 kg/m2 as a reference range: the rate of all-cause mortality tended 
to increase not only in the BMI range of below 22.5 (or 25) kg/m2 but also in BMI range of above 
25 kg/m2.11,12 However, unlike the previous studies, in this study, the BMI range, where the 
largest number of AAV patients died (44.0%), was between 22.1 and 25.0 kg/m2. It could be 
assumed that this discrepancy was derived from the different study-subjects between general 
people and AAV patients and furthermore, it might offset the high calculated BMI in male 
patients from contributing to an increased all-cause mortality rate.
A previous study, male sex was significantly associated with ESRD occurrence compared 
to female sex in AAV patients with histologically proven pauci-immune necrotising 
glomerulonephritis.5 However, unlike the previous study, no significant difference in the 
cumulative ESRD-free survival rate between male and female patients in this study. Although 
not all patients with renal involvement underwent renal biopsy, to reproduce the result 
of the previous study, we included only AAV patients with renal involvement (50 men and 
86 women) and analysed it again. However, we could find no significant difference in the 
cumulative ESRD-free survival rates between male and female patients during the follow-up 
period based on ESRD (P = 0.994) (Supplementary Fig. 1). Therefore, although focusing on 
AAV patients with renal involvement, we conclude that the male sex was turned out to be not 
a good predictor of ESRD during follow-up.
We wondered whether male sex may differently affect the cumulative patients' survival 
rates among AAV-subtypes. Therefore, we conducted the Kaplan-Meier survival analysis for 
comparing the cumulative patients' survival rates between male and female patients in each 
AAV subtypes. Among MPA patients, male patients exhibited a significantly lower cumulative 
survival rate than female patients. However, no significant difference in the cumulative 
survival rates was observed between male and female patients among GPA patients 
(Supplementary Fig. 2). On the other hand, since all EGPA patients survived during the 
follow-up period, the analysis regarding the clinical significance of sex for all-cause mortality 
was not performed in EGPA patients. With these results, we conclude that the male sex 
could reduce significantly the cumulative patients' survival rates in MPA patients compared 
to GPA patients. However, in real clinical settings, since there are not a few cases where the 
differential diagnosis between MPA and GPA may be difficult, we intend to maintain the 
current title including AAV patients rather than MPA patients.
In this study, variables with P value less than 0.005 in the univariable Cox hazard model 
analysis were restrictively included in the multivariable analysis. However, since we cannot 
ignore the variables that were found to be associated with mortality in previous studies, we 
considered including these variables in multivariate analysis. Since BMI showed a ‘U shape’ 
contribution to the rate of all-cause mortality, BMI cannot be included in the multivariable 
analysis. Whereas, ANCA type was reported to be associated with the mortality rate or the 
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infectious cause of death in AAV patients.13 Therefore, we consider including MPO-ANCA 
(or P-ANCA) and PR3-ANCA (or C-ANCA) in the multivariable Cox hazards model analysis, 
however, both of them exhibited too low statistical significance in the univariable analysis to 
be included in the multivariable analysis. On the other hand, CRP tended to be significantly 
associated with all-cause mortality during the follow-up period (P = 0.073) and furthermore, 
an index consisting of CRP and other variables was reported to be an independent predictor 
of all-cause mortality in AAV patients.14 Therefore, we conducted the multivariable Cox 
hazards model analysis by including CRP. However, similar to the results from Table 3, only 
male sex and FFS at diagnosis exhibited statically significant HR in the multivariable analysis, 
despite the addition of CRP. Therefore, we decided to maintain the results of Table 3.
The retrospective design might weaken the power of the clinical implication of the sex 
difference that our study provided. Also, the number of patients was not large enough to 
represent all Korean patients with AAV. However, this study might be valuable in that this is 
the first study which provided information regarding the differences in the clinical features 
and prognosis in the course of AAV between male and female AAV patients in Korea. Also, 
the limitation of the monocentric study may paradoxically minimise the inter-centric 
variation or bias, which could enhance the reliability of our study. Most deaths from septic 
shock or cancer were more frequent than death from persistent haemoptysis or damage to 
major organs such as the brain and heart. However, since there were many cases in which 
it was impossible to accurately classify the cause of their death, this study used the item of 
all-cause mortality without classifying death by cause, which was an additional limitation 
of this study. We believe that a prospective future study with a larger number of patients by 
recruiting the institutes, where the same inclusion criteria can be applied and the electronic 
medical records can be shared, will provide more reliable and valuable information.
In conclusion, male sex did not affect the clinical features at diagnosis, however, it increased 
the rate of all-cause mortality during the follow-up of AAV and was proved to be an 
independent predictor of all-cause mortality in AAV patients.
SUPPLEMENTARY MATERIALS
Supplementary Fig. 1
Comparison of the cumulative ESRD-free survival rate between male and female patients 
with AAV having renal involvement at diagnosis.
Click here to view
Supplementary Fig. 2
Comparison of the cumulative patients' survival rates between male and female patients who 
were classified as either MPA or GPA.
Click here to view
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